Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Poop pills for ICU patients? small study shows promise for gut troubles

NCT ID NCT06603883

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether transplanting healthy gut bacteria (fecal microbiota transplantation) could help critically ill ICU patients who have trouble tolerating tube feeding due to gut problems. Nineteen patients received the treatment to see if it improved their ability to digest food, reduced inflammation, and shortened hospital stays. The goal was to find a new way to manage a common complication in intensive care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

19 people

The number who actually took part.

Started

Oct 2024

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. 8 ≤ age ≤ 70 years old, any nationality, any gender; 2. Female patients have no potential fertility (i.e., no physical ability to conceive, including women who have been menopausal for 2 years) or no pregnancy plan; 3. Patients who have been in the ICU for at least 24 hours; 4. Patients with an expected ICU stay of at least 7 days; 5. Non-acute patients with at least one manifestation of gastrointestinal dysfunction leading to enteral nutrition intolerance; 6. Patients can cooperate or passively complete the relevant examination and complete the follow-up; 7. Informed consent is documented by means of a written, signed and dated informed consent form. Exclusion Criteria: 1. Severe systemic infection, in early recovery period, hemodynamic instability or tissue hypoperfusion, severe imbalances in water and electrolyte status; 2. Patients who are considered by clinicians to be at high risk of death within 5 days, or who are subject to restricted treatment decisions; 3. Severe damage of intestinal barrier such as active massive bleeding and perforation of digestive tract; 4. Patients who cannot tolerate 50% of caloric calorie requirements with enteral nutrition due to severe diarrhea, significant fibrous intestinal stenosis, severe gastrointestinal bleeding, high-flow intestinal fistula and other reasons; 5. Nasal jejunal tube cannot be placed; 6. Planned or recent abdominal surgery (within 14 days); 7. Currently diagnosed with fulminant colitis or toxic megacolon; 8. Neutropenia (neutrophil count \< 1500 /µL); 9. Patients with congenital or acquired immune deficiency; 10. Malignant hematologic diseases, such as lymphoma; 11. Autoimmune diseases; 12. Patients who have recently received high-risk immunosuppressive or cytotoxic drugs, such as rituximab, doxorubicin, or medium-high dose of steroid hormones (20mg/day or higher) for more than 4 weeks; 13. Pregnant or lactating women; 14. Participating in other clinical studies as a participant at the time of enrollment or within 3 months before inclusion; 15. Informed consent can not be obtained.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal dysfunction-induced enteral nutrition intolerance are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China

  • Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China